Each entry provides detailed information of the peptide, like its name, sequence, half-life, modifications, the experimental assay for determining half-life, biological nature and activity of the peptide
doi: 10.2337/diacare.28.5.1092 214 GujaCFrasJPSomogyiAJabbourSWangHHardyEet al
Some studies suggest potential benefits, while others find no significant impact on weight loss
[DOI] [PMC free article] [PubMed] [Google Scholar] 252.Van Skike C.E., Jahrling J.B., Olson A.B., Sayre N.L., Hussong S.A., Ungvari Z., Lechleiter J.D., Galvan V
Primary outcome: Percentage change in body weight and the proportion of participants who lost at least 5% of baseline weight by week 68 Results: Primary outcome (% weight loss): Wegovy - 16%, Placebo - 5.7% (p 35 - 68.9% Randomized treatment groups Group 1 (374 patients): Tirzepatide titrated to the maximum tolerated dose of 10 mg or 15 mg once weekly Group 2 (376 patients): Semaglutide titrated to the maximum tolerated dose of 1.7 mg or 2.4 mg once weekly Tirzepatide was initiated at a dose of 2.5 mg once weekly, and the dose was increased by 2.5 mg every 4 weeks until a maximum tolerated dose of 10 mg or 15 mg was reached
